Nxera Pharma Co., Ltd. Logo

Nxera Pharma Co., Ltd.

Biopharma using SBDD tech to develop medicines for neurology and gastroenterology.

4565 | T

Overview

Corporate Details

ISIN(s):
JP3431300007
LEI:
Country:
Japan
Address:
港区赤坂9−7−2
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Nxera Pharma Co., Ltd. (formerly Sosei Group) is a technology-driven biopharmaceutical company focused on the discovery and development of specialty medicines. Its mission is to accelerate the creation of life-changing treatments for patients with unmet medical needs, both in Japan and globally. The company leverages its proprietary structure-based drug design (SBDD) platform and drug development capabilities to advance a diverse pipeline of therapeutic programs. Nxera Pharma actively seeks partnerships to pursue breakthrough discoveries and bring innovative medicines to market, with a focus on areas such as neurology and gastroenterology.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-08 09:06
Regulatory News Service
訂正有価証券届出書(参照方式)
Japanese 41.8 KB
2025-08-08 09:05
Regulatory News Service
訂正有価証券届出書(参照方式)
Japanese 41.8 KB
2025-08-08 08:57
Report Publication Announcement
確認書
Japanese 8.4 KB
2025-08-08 08:55
Interim Report
半期報告書-第36期(2025/01/01-2025/12/31)
Japanese 287.5 KB
2025-04-16 08:57
Registration Form
訂正有価証券届出書(参照方式)
Japanese 41.6 KB
2025-04-16 08:55
Registration Form
訂正有価証券届出書(参照方式)
Japanese 41.6 KB
2025-04-16 08:53
Registration Form
訂正有価証券届出書(参照方式)
Japanese 39.8 KB
2025-04-16 08:51
Remuneration Information
臨時報告書
Japanese 32.4 KB
2025-03-26 08:42
Regulatory News Service
訂正有価証券届出書(参照方式)
Japanese 42.2 KB
2025-03-26 08:41
Regulatory News Service
訂正有価証券届出書(参照方式)
Japanese 42.2 KB
2025-03-26 08:40
Regulatory News Service
訂正有価証券届出書(参照方式)
Japanese 40.4 KB
2025-03-26 08:38
Regulatory News Service
臨時報告書
Japanese 28.0 KB
2025-03-26 08:37
Regulatory News Service
内部統制報告書-第35期(2024/01/01-2024/12/31)
Japanese 23.8 KB
2025-03-26 08:36
Regulatory News Service
確認書
Japanese 8.6 KB
2025-03-26 08:35
Annual Report
有価証券報告書-第35期(2024/01/01-2024/12/31)
Japanese 1.3 MB

Automate Your Workflow. Get a real-time feed of all Nxera Pharma Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Nxera Pharma Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Nxera Pharma Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

ABIONYX Pharma Logo
Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.
France
ABNX
Abliva Logo
Develops clinical-stage medicines for rare primary mitochondrial diseases to restore cell function.
Sweden
ABLI
Abpro Holdings, Inc. Logo
Clinical-stage biotech developing antibody therapies for oncology & ophthalmology.
United States of America
ABP
AB Science Logo
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
France
AB
ACADIA PHARMACEUTICALS INC Logo
Develops and commercializes innovative therapies for CNS disorders and rare diseases.
United States of America
ACAD
Access Bio, Inc. Logo
Develops and manufactures rapid diagnostic tests for infectious diseases for global health.
United States of America
950130
ACHIEVE LIFE SCIENCES, INC. Logo
Developing cytisinicline, a plant-based treatment for smoking cessation and nicotine addiction.
United States of America
ACHV
AC Immune SA Logo
Developing precision medicine to diagnose, treat, and prevent neurodegenerative diseases.
United States of America
ACIU
Aclaris Therapeutics, Inc. Logo
A clinical-stage biopharma developing novel drugs for immuno-inflammatory diseases.
United States of America
ACRS
Actinium Pharmaceuticals, Inc. Logo
Develops targeted radiotherapies for advanced cancers like AML and prostate cancer.
United States of America
ATNM

Talk to a Data Expert

Have a question? We'll get back to you promptly.